The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast revenues of $2.77 billion, representing an increase of 10% year over year.Over the last 30 days, there has been a downward revision of 2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.Last week, the company announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The drug will be marketed by the name of Journavx ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.Per the company, Journavx has the potential to ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx. In a statement to the press, the company said it was the "first new class of pain treatment approved in more than 20 years." In response, Scotiabank raised its price target on VRTX by $3 to $433. Now recovered from its mid-December bear gap, VRTX is already up 15.7% since the start of 2025. Today's pop has the stock b ...

POLAND - 2024/11/21: In this photo illustration, the Vertex Pharmaceuticals company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesVertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales. For perspectiv ...

Stock Performance - Vertex Pharmaceuticals closed at $440 68, down 0 72% from the previous session, underperforming the S&P 500's gain of 0 92%, the Dow's gain of 0 31%, and the Nasdaq's gain of 2 03% [1] - Over the past month, the company's shares gained 11 15%, outperforming the Medical sector's gain of 3 83% and the S&P 500's gain of 0 81% [1] Earnings and Revenue - The company's upcoming earnings report is expected on February 10, 2025, with projected EPS of $4, reflecting a 4 76% decrease from the same quarter last year [2] - Revenue is expected to be $2 78 billion, up 10 29% from the prior-year quarter [2] Analyst Forecasts and Revisions - Recent revisions to analyst forecasts for Vertex Pharmaceuticals are important as they reflect changing near-term business trends [3] - Positive estimate revisions are generally a good sign for the company's business outlook [3] - The Zacks Consensus EPS estimate has shifted 0 34% downward over the past month [5] Valuation Metrics - Vertex Pharmaceuticals is trading at a Forward P/E ratio of 24 39, which is a premium compared to the industry average of 22 85 [6] - The company has a PEG ratio of 2, higher than the industry average of 1 39 for Medical - Biomedical and Genetics stocks [6] Industry Ranking - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [7] - Top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, t ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and the Nasdaq, a tech-heavy index, added 1.28%.Shares of the drugmaker have appreciated by 4.83% over the course of the past month, outperforming the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08%.Analysts and investors alike will be keeping a close eye on the performance of V ...

VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated ...

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky ...